Skip to Content
Søk Menu

Prolonged Progression-Free Survival in Patients with Advanced Ovarian Cancer

Results from ASCO23 provide encouraging evidence for a novel treatment approach using durvalumab and olaparib in addition to the standard of care for patients with advanced ovarian cancer.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

ASCO GU 2024: Updated Results from AVENANCE – Real-World Effectiveness of Avelumab in Patients with Advanced Urothelial Carcinoma

/ Sofie Pohl
ASCOGU24Gynekologisk kreft

The 2024 ASCO Genitourinary Cancers Symposium Will Be Covered by BestPractice Nordic

/ Sofie Pohl
ASCOGU24Gynekologisk kreft
Kristina Lindemann

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Kristina Lindemann
ESMO23Gynekologisk kreftPasientinvolvering Play the Video 05:30
Kristina Lindemann

Potential New Standard of Care for Locally Advanced Cervical Cancer

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video 03:28
Mansoor Raza Mirza

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video 02:45
Kristina Lindemann

Oppdatering fra ESMO 2023 med fokus på kreft i livmorhals-, livmor- og endometrie

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video 04:30

Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

/ Shannon Westin
ESMO23Gynekologisk kreft Play the Video 1:38
Mansoor Raza Mirza

New Treatment Possibilities for Patients with Recurrent or Primary Advanced Endometrial Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video 4:31
Shannon Westin

Insights on Duo-E Trial: Advancing Endometrial Cancer Treatment with Olaparib

/ Shannon Westin
ESMO23Gynekologisk kreft Play the Video 4:06
Back to top